Fremanezumab-Vfrm
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Zavegepant (Zavzpret) for acute treatment of migraine.
Journal: The Medical letter on drugs and therapeutics
Published: July 17, 2023
Comparison table: Some drugs for migraine prevention in adults.
Journal: The Medical letter on drugs and therapeutics
Published: June 02, 2023
Atogepant (Qulipta) for migraine prevention.
Journal: The Medical letter on drugs and therapeutics
Published: January 27, 2022
Fremanezumab autoinjector pen for the prevention of migraine.
Journal: Therapeutic delivery
Published: August 16, 2021
Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach.
Journal: Cephalalgia : an international journal of headache
Published: May 18, 2021
In brief: Hypertension with erenumab (Aimovig).
Journal: The Medical letter on drugs and therapeutics
Published: April 08, 2021
Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY®) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study.
Journal: Pharmaceutics
Published: March 17, 2021
A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe.
Journal: Clinical pharmacology in drug development
Published: October 22, 2020
Eptinezumab (Vyepti) for migraine prevention.
Journal: The Medical letter on drugs and therapeutics
Published: June 20, 2020
Last Updated: 04/28/2026